BioCentury
ARTICLE | Product Development

CNTO says housecleaning is done

June 7, 1993 7:00 AM UTC

Centocor Inc. hopes that it has dropped the last shoe with its withdrawal of product license applications for Myoscint and Fibriscint, culminating a wrenching series of surprises and course corrections at the company. David Holveck, president and CEO, told BioCentury that the withdrawals mark the end of CNTO's audits of all of its PLA filings.

The independent audits, conducted by the Atlanta law firm King & Spalding, were started in 1992 at the request of the FDA, following the controversy surrounding CNTO's HA-1A antibody to treat sepsis. ...